secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0000950170-23-032763
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen to acquire Physio-Assist for up to $45M; prelim Q2 rev $83-84M
---------------------------------------------------------------------

- Acquires Physio-Assist for ~$32M cash at closing plus up to $13M on FDA clearance milestones; total capped at $45M.
- Simeox airway clearance device (CE marked) expands product line; US market opportunity estimated at 400k-490k bronchiectasis patients.
- Closing expected Q4 2023 subject to French regulatory approval; Inogen provides up to $500k convertible loan pre-close.
- Preliminary Q2 2023 revenue $83-84M, below expectations; updated 2023 guidance to follow on Aug 7 earnings call.
- Acquisition expected to be accretive to adjusted earnings from 2027 and immediately accretive to gross margin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/0000950170-23-032763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017023032763/ingn-20230710.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-032763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer